ABBV vs LLY
AbbVie Inc. Common Stock vs Eli Lilly and Company Common Stock. Scores ACCE, valorisation, rentabilité et croissance côte à côte.
$LLY vs $ABBV: Lilly Takes It
$LLY is the clear winner here, backed by an ACCE score of 75 vs $ABBV's 60, and the numbers justify the gap.
Growth is the headline. Lilly posted 55.5% revenue growth year-over-year and earnings growth of 169.9% — a performance that earns it a perfect Growth score of 100/100. $ABBV, by contrast, grew revenue 12.4% but saw earnings collapse 46.2% over the same period.
Quality reinforces the case. $LLY carries a Quality score of 86/100, an ROE of 107.5%, and a net margin of 35.0%. $ABBV's 5.8% net margin looks thin by comparison, even if its 62.3% ROE reflects financial engineering via its deeply negative debt-to-equity.
The catch on both names is valuation. $LLY's 6-model fair value sits at $148.55 — implying significant premium to intrinsic value at current prices. $ABBV's fair value of $180.10 suggests similar overextension at $258.15. Neither is cheap.
For growth-oriented exposure, $LLY's momentum (90/100), earnings trajectory, and margin profile make it the stronger pick. $ABBV's 2.6% dividend and lower forward P/E of 18.2 offer income appeal, but the earnings decline is a real concern.